iShares Global Tech ETF vs Liquidia Corporation Common Stock — how do they compare? iShares Global Tech ETF trades at $141 (market cap $9.75B), while Liquidia Corporation Common Stock trades at $34.9 (market cap $2.40B). The key difference: iShares Global Tech ETF is far larger — about 4.1× Liquidia Corporation Common Stock's market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 48 Days and Liquidia Corporation Common Stock for 0 Days on average.
| IXN | LQDA | |
|---|---|---|
Market Cap | $9.75B | $2.40B |
Volume | 365,991 | 2,857,547 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $91.03 |
52-Week Low | $95.76 | $22.02 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $2.30B |
Signals from Pluang's Aura AI — not financial advice
IXN (iShares Global Tech ETF) trades at $147.07, down 0.49% on the day but maintains a bullish technical signal with strong moving average support. The ETF recently hit a 52-week high, reflecting momentum despite current consolidation. Technical indicators show mixed signals with neutral RSI readings but bearish ADX trends, while support levels cluster around $146-147.
The outlook remains constructive given the ETF's exposure to global technology leaders and attractive valuation metrics. Key risks include concentration in tech stocks and AI sector volatility. Analyst sentiment appears positive with recent buy ratings citing compelling valuations and long-term growth potential in the global tech landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →